| gap-debate-20260410- | What is the direct mechanistic link between TREK-1 channel activation and AQP4 p | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | Do grid cell firing deficits result from intrinsic membrane properties or circui | resolved | 0.70 | 0.00 | 2026-04-10 | 0 | | systems-neuroscience |
| gap-debate-20260410- | Can tau-independent microtubule stabilization compensate for tau pathology in vi | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What makes EC layer II stellate neurons uniquely vulnerable compared to other co | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Is HCN1 dysfunction causal or protective in EC layer II neurodegeneration? | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Does transglutaminase-2 cross-linking occur during initial cross-seeding or only | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Can engineered TREM2 receptors selectively clear cross-seeded aggregates without | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | What are the structural determinants that enable cross-seeding between different | open | 0.85 | 0.00 | 2026-04-10 | 0 | | structural-biology |
| gap-debate-20260410- | Does DNAJB6 directly inhibit cross-seeding between tau, α-synuclein, and TDP-43 | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Does CD38 inhibition impair essential immune functions of NK cells and T cells i | open | 0.70 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | How can complement inhibitors be selectively targeted to senescent cell microenv | open | 0.75 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | What is the relative contribution of senescent cell CD38 vs other sources to neu | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Do senescent cells create discrete NAD+ depletion zones or cause global NAD+ red | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do butyrate and other SCFAs modulate microglial phenotypes through GPR109A v | open | 0.70 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Which specific bacterial taxa drive the shift from neuroprotective to neurotoxic | open | 0.75 | 0.00 | 2026-04-10 | 0 | | microbiology |
| gap-debate-20260410- | What is the temporal relationship between gut dysbiosis and CNS α-synuclein path | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 1 | 2026-04-12 | neurodegeneration |
| gap-debate-20260410- | Which cryptic exon inclusion events are functionally relevant versus bystander e | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What is the causal relationship between mitochondrial RNA transport defects and | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do cell-type specific differences in RBP expression patterns affect therapeu | open | 0.85 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What determines the temporal transition from protective to pathological stress g | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the temporal dynamics and reversibility of synthetic biology approaches | open | 0.75 | 0.00 | 2026-04-10 | 0 | | synthetic-biology |
| gap-debate-20260410- | How do Fc domain modifications affect microglial activation and ARIA risk in eng | open | 0.80 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Does transferrin receptor clustering enhance or impair transcytosis efficiency a | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What is the actual quantitative contribution of FcRn-mediated transcytosis to BB | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | Do TET2 mutations directly cause neurodegeneration or reflect systemic inflammat | resolved | 0.70 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What is the therapeutic window for HDAC3 inhibition that preserves circadian fun | open | 0.75 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | How can TET2 overexpression achieve site-specific demethylation without global g | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Are age-related DNA methylation changes protective adaptations or pathological d | investigating | 0.90 | 0.00 | 2026-04-10 | 1 | 2026-04-26 | neurodegeneration |
| gap-debate-20260410- | What is the therapeutic window for P2Y12 modulation between efficacy and immunoc | open | 0.80 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | Can complement-independent pruning pathways compensate for C1q inhibition? | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | What determines context-dependent C1q binding outcomes at synapses? | open | 0.85 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Is C1q elevation in AD pathogenic or compensatory for amyloid clearance? | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the endogenous signals that trigger astrocytes to initiate mitochondria | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuron-glia-interactions |
| gap-debate-20260410- | How do transferred mitochondria integrate functionally with recipient neuron bio | open | 0.80 | 0.00 | 2026-04-10 | 0 | | mitochondrial-biology |
| gap-debate-20260410- | Do tunneling nanotubes represent the primary pathway for mitochondrial transfer | open | 0.85 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | What are the molecular determinants that control directional mitochondrial trans | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | cellular-neuroscience |
| gap-debate-20260410- | Can small molecules achieve selective binding to APOE4 versus APOE3 isoforms wit | open | 0.70 | 0.00 | 2026-04-10 | 0 | | drug-discovery |
| gap-debate-20260410- | What determines the efficiency and specificity of base editing in post-mitotic n | open | 0.75 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-debate-20260410- | How does APOE4 conformation differ between lipid-free and lipid-associated state | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurobiochemistry |
| gap-debate-20260410- | What is the high-resolution structure of the APOE4 hinge region and its role in | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | structural-biology |
| gap-debate-20260410- | What CNS penetration strategies can achieve therapeutic concentrations of proteo | open | 0.69 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | How do individual chronotype variations affect standardized circadian-based ther | open | 0.71 | 0.00 | 2026-04-10 | 0 | | personalized-medicine |
| gap-debate-20260410- | Is circadian disruption a cause or consequence of early neurodegeneration pathol | open | 0.78 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | What are the optimal circadian timing windows for proteostasis enhancer delivery | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How does cholesterol gradient disruption differentially affect amyloidogenic vs | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | Can selective acid sphingomyelinase modulators achieve therapeutic ceramide redu | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | What are the optimal CYP46A1 expression levels needed to normalize cholesterol w | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | How do sphingomyelin/ceramide ratios specifically regulate BACE1 clustering and | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How can TREM2 modulation be restricted to microglia without affecting oligodendr | open | 0.75 | 0.00 | 2026-04-10 | 0 | | drug-delivery |